Although TNF-alpha inhibitors remain the most widely prescribed biologics for rheumatoid arthritis (RA) refractory to conventional DMARD treatment (the first-line standard of care), the RA drug market boasts a variety of targeted agents from many drug classes, all competing largely for a share of the TNF-refractory population. The continued launch of biosimilars in the major pharmaceutical markets will only add to the competition. Increasing safety concerns surrounding the JAK inhibitor class have delayed their use until after anti-TNF drugs in the United States, reducing their overall uptake. Although the late-phase pipeline for RA is sparse, the sheer number of biologics and targeted oral therapies available to treat the disease ensures that marketers will face fierce competition and increasing challenges to gain and maintain market share.<\/p>\n
Questions answered<\/strong><\/p>\n Content highlights<\/strong><\/p>\n Markets covered: United States, EU5, Japan<\/p>\n Primary research: 29 country-specific interviews with thought-leading rheumatologists<\/p>\n Epidemiology: Number of total, diagnosed, and drug-treated prevalent cases of RA by country; number of diagnosed prevalent cases of RA by severity<\/p>\n Forecast: 10-year, annualized, drug-level sales and patient share of key RA\u00a0therapies through 2034, segmented by brands \/ generics \/ biosimilars<\/p>\n Drug treatments: Coverage of key current and late-phase emerging therapies<\/p>\n Product description<\/strong><\/p>\n Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:<\/p>\n\n
\n